Abstract P5-19-11: Noninterventional study HELENA – Advanced (metastatic or locally recurrent, inoperable) HER2-positive breast cancer: First-Line trEatmeNt with pertuzumAb after adjuvant trastuzumab therapy. 7. Juli 2014 Thill, M., Ziegler-Löhr, K., Wagner, H., Helling-Giese, G., Greinemann, J., Schmalhofer, O., Reichert, D., 2015. Cancer Res 75 (9 Suppl)(P5-19–11). doi:10.1158/1538-7445.SABCS14-P5-19-11 Abstract Quality of Life under Capecitabine (Xeloda®) in Patients with Metastatic Breast Cancer: Data from a German Non-Interventional Surveillance Study. Müller, V., Fuxius, S., Steffens, C.-C., Lerchenmüller, C., Luhn, B., Vehling-Kaiser, U., Hurst, U., Hahn, L.-J., Soeling, U., Wohlfarth, T., Zaiss, M., 2014. Oncol Res… Weiterlesen Bendamustine as first-line treatment in patients with advanced indolent non-Hodgkin lymphoma and mantle cell lymphoma in German routine clinical practice. Becker, M., Tschechne, B., Reeb, M., Schwinger, U., Bruch, H.-R., Frank, M., Straßl, L., 2015. Ann Hematol 94, 1553–1558. doi:10.1007/s00277-015-2404-1… Weiterlesen